Neuronetics, INC Form 4 insider transactions

Jorey Chernett, a 10% owner of Neuronetics, Inc., purchased 35,000 shares of common stock on July 14, 2026 for $1.78 per share.

Director Avinash Amin transferred shares of Neuronetics, Inc. common stock to affiliated Madryn Health Partners funds as part of director compensation.

Madryn Asset Management, LP and affiliated entities have reported changes in their beneficial ownership of Neuronetics, Inc. common stock.

Director Megan Rosengarten was granted 30,000 restricted stock units by Neuronetics, Inc. as part of an equity award.

Director Glenn P. Muir was granted 30,000 restricted stock units by Neuronetics, Inc. on May 28, 2026.

Director Sasha Cucuz was granted 30,000 restricted stock units by Neuronetics, Inc. as part of an equity compensation award.

Director Sheryl L. Conley was granted 30,000 restricted stock units in Neuronetics, Inc. as part of an equity award.

Director Robert Cascella was granted 36,250 restricted stock units by Neuronetics, Inc. as part of his compensation.

Director Avinash Amin was granted 30,000 restricted stock units in Neuronetics, Inc. as part of an equity compensation award.

Steven Pfanstiel, former EVP, CFO and Treasurer of Neuronetics, Inc., reported a minor adjustment in his beneficial ownership of common stock.

Jorey Chernett, a Director at Neuronetics, Inc., acquired 100,000 shares of common stock on May 19, 2026, at a price of $1.17 per share.

Jorey Chernett, a director and 10% owner of Neuronetics, Inc., acquired 475,000 shares of common stock in a series of transactions.

Director Jorey Chernett acquired 200,000 shares of Neuronetics, Inc. common stock through multiple transactions on April 20-21, 2026.

Madryn Asset Management's affiliated funds reallocated 337,312 Neuronetics common shares for internal fund administration purposes.

Neuronetics Director and 10% owner Jorey Chernett acquired 385,442 shares of common stock for approximately $481,802 on March 30, 2026, increasing beneficial ownership to 9,778,988 shares.

10% owner Jorey Chernett purchased 500,000 Neuronetics shares at a $1.35 average price, lifting his direct stake to 9,393,276 shares.

Neuronetics Director and 10% owner Jorey Chernett acquired 150,000 shares of common stock in late March 2026, increasing his direct beneficial ownership.

Neuronetics' EVP, CFO, and Treasurer, Steven Pfanstiel, sold 16,431 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Former Neuronetics officer Keith J. Sullivan sold 46,289 shares of common stock to cover tax withholding obligations from a restricted stock unit award.

Neuronetics' EVP, CLO, and CS, William Andrew Macan, sold 16,005 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Neuronetics, Inc. President and CEO Daniel L. Reuvers was granted 1.5 million restricted stock units, vesting over three years.

Neuronetics Director and 10% Owner Jorey Chernett acquired 169,472 shares of common stock for approximately $238,855.

Neuronetics Director and 10% Owner Jorey Chernett acquired over 1 million shares of common stock in open market purchases.

Neuronetics, Inc. President and CEO Keith J. Sullivan increased his direct beneficial ownership by 112,500 shares of common stock through the vesting of performance-based restricted stock units.

Neuronetics, Inc.'s EVP, CLO, and CS, William Andrew Macan, acquired 33,750 shares of common stock for no consideration through a performance-based restricted stock unit award.

Neuronetics, Inc.'s EVP, CFO, and Treasurer, Steven Pfanstiel, was granted 25,000 restricted stock units vesting over three years.

Neuronetics' Executive Vice President and Chief Legal Officer, William Andrew Macan, sold 609 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Neuronetics EVP, CLO, and CS William Andrew Macan sold 3,427 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Neuronetics, Inc. President and CEO, Keith J. Sullivan, sold 8,452 shares of common stock to cover tax withholding obligations related to a restricted stock unit award.

Neuronetics, Inc.'s EVP, CFO, and Treasurer, Steven Pfanstiel, was granted 250,000 restricted stock units vesting over three years.